Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

Noel W. Clarke,Paweł Wiechno,Boris Y. Alekseev,Núria Sala,Robert Jones,Ivo Kocák,Vincenzo Emanuele Chiuri,Jacek Jassem,Aude Flechon,Charles H. Redfern,Carsten Dietrich Goessl,Joseph Burgents,Robert Kozarski,Darren Hodgson,Fred Saad

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

2018

Noel W. Clarke
Paweł Wiechno
Boris Y. Alekseev
Núria Sala
Robert Jones
Ivo Kocák
Vincenzo Emanuele Chiuri
Jacek Jassem
Aude Flechon
Charles H. Redfern
Carsten Dietrich Goessl
Joseph Burgents
Robert Kozarski
Darren Hodgson
Fred Saad

5003Background: mCRPC pts with a homologous recombination repair mutation (HRRm) previously showed improved response to the PARP inhibitor olaparib (Lynparza) as monotherapy vs pts without a HRRm (...

Keywords:

Abiraterone
Prostate cancer
Physical therapy
Olaparib
Castration
Cancer research
Medicine
Homologous recombination
Oncology
in patient
Internal medicine
castration resistant
PARP inhibitor
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations